Strategic partnerships within language and translation services
Managed Service Providers ensure our businesses have competitive advantage in service, quality, responsiveness and cost in the global market, especially in the area of language and translation services.
As the outsourcing market continues to grow, building long-term partnerships with a limited number of trusted vendors has become an essential part of the development, manufacturing and commercialisation process in the pharmaceutical/biotech industry. The objective is to develop strategic partnerships that help lower costs while creating efficiencies in the value chain.
By definition, a Managed Service Provider (MSP) is an outsourced third-party organisation that assumes the responsibility for managing several defined services and functions. Over the last few years, this concept has become increasingly relevant in the Language Services space, where larger and smaller Life Sciences companies face the ongoing challenge of managing countless local and global Language Service Providers (LSPs) with little visibility and control on the overall translation strategy.
In an environment where accelerating time to market for new drugs and close monitoring of costs and quality becomes a priority, a centralised approach to the Language Services strategy is of utmost importance. While the MSP solution needs to be flexible and tailored for each organisation based on their needs and goals, there are five key components to consider for a successful MSP program. These are:
- Centralised Translation Memory: Consolidating all outstanding translated content across existing and past vendors is the first step to building a “golden” library; a single medium that allows for increased quality and consistency, faster timelines and reduced costs.
- Suitable LSPs: While it is important to guarantee minimal disruption, especially at a local level, for this program to succeed, it is recommended to select 3-4 key LSP partners that can provide the right level of support and cultural fit for each content type and language pair.
- Vendor agnostic technology platform: A technology portal is essential to ensure all users and LSPs can interact in the same environment. Technology is critical to facilitating automation, tracking, reporting and alignment.
- Quality assurance team: These teams help in defining and implementing robust governance plans for all the parties involved to manage delivery expectations and identify means to drive continuous improvement (KPIs, SLAs, feedback tracking, auditing, etc.).
- Finance team: Taking care of reporting, tracking savings and preparing invoicing on behalf of the sponsor falls within the purview of this team. It provides a detailed level of visibility and data into the translation program that many pharma companies struggle to achieve.
Managed Service Providers start at the beginning, thoroughly reviewing all current processes and with minimal disruption, implementing an integrated solution-oriented program where all involved parties work together seamlessly and act in the sponsor’s best interest. Overall, having an MSP partner that acts as an extension of your team provides you with access to industry experts, enhanced visibility of your translation program and custom-based infrastructure, so that your team can focus on the core business functionalities.
If you would like to learn more about an MSP program, contact us today.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel